METHODS AND COMPOSITIONS FOR MINIMALLY INVASIVE CAPSULAR AUGMENTATION OF CANINE COXOFEMORAL JOINTS

• US 20100004699A1
• Filed: 03/04/2009
• Published: 01/07/2010
• Est. Priority Date: 03/05/2008
• Status: Active Grant

• Current Assignee: Neville Alleyne, Stuart Young
• Original Assignee: Neville Alleyne, Stuart Young
• Inventors: Young, Stuart, Alleyne, Neville
• Granted Patent: US 8,469,961 B2
• Time in Patent Office: Days
• US Class Current: 606/86.R
• CPC Class Codes: A61F 2/08 Muscles; Tendons; Ligaments sutures A61B17/04
• CPC Class Codes: A61F 2/30742 Bellows or hose-like seals; Sealing membranes A61B17/8808 takes precedence; sealing membranes for retaining bone substitute A61F2/2846
• CPC Class Codes: A61F 2/32 for the hip
• CPC Class Codes: A61F 2002/30588 filled with solid particles
• CPC Class Codes: A61F 2002/30677 Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body
• CPC Class Codes: A61F 2002/307 Prostheses for animals
• CPC Class Codes: A61F 2310/00365 Proteins; Polypeptides; Degradation products thereof

Abstract

The present technology relates to methods and devices for augmenting the canine coxofemoral joint. In particular, methods for augmenting the capsule of the canine coxofemoral joint are provided. In some embodiments, augmentation can be performed by injecting an implantable device comprising a biodegradable matrix and microparticles into the capsule. In some embodiments, augmentation can be performed by imbricating an implantable device comprising a biodegradable matrix and microparticles at the capsule.

Claims

1. A method for augmenting the capsule of a coxofemoral joint in a canine subject comprising:

identifying a subject in need of coxofemoral capsular augmentation;

delivering an implantable device to said coxofemoral capsule, wherein said implantable device comprises a biodegradable matrix and a plurality of microparticles; and

contacting said implantable device with at least a portion of said capsule.

2. The method of claim 1, wherein said implantable device comprises a sheet.

3. The method of claim 2, wherein said sheet comprises fenestrations.

4. The method of claim 2, further comprising anchoring said implantable device at said joint.

5. The method of claim 4, wherein said anchoring is at one or more sites of said joint selected from the capsule, iliofemoral ligament, ischiocapsular ligament, pubocapsular ligament, acetabular labrum, ligamentum teres femoris, acetabulum, or femoral neck.

6. The method of claim 1, wherein said delivering comprises injecting said implantable device into one or more sites of said capsule.

7. The method of claim 6, wherein said one or more sites are selected from the capsule, iliofemoral ligament, ischiocapsular ligament, pubocapsular ligament. acetabular labrum, or ligamentum teres femoris.

8. The method of claim 6, wherein said injecting is into at least a portion of the stratum fibrosum of said capsule.

9. The method of claim 1, wherein said contacting said implantable device with at least a portion of said joint comprises at least a portion of one or more sites selected from the capsule, iliofemoral ligament, ischiocapsular ligament, pubocapsular ligament, acetabular labrum, or ligamentum teres femoris.

10. The method of claim 1, wherein said joint has undergone capsulotomy or partial capsulectomy.

11. The method of claim 1, wherein said delivering comprises percutaneous delivery.

12. The method of claim 1, wherein said delivering comprises an open surgical procedure.

13. The method of claim 1, wherein said biodegradable matrix comprises bovine collagen.

14. The method of claim 1, wherein said biodegradable matrix comprises one or more materials selected from albumin, gelatin, chitosan, hyaluronic acid, starch, cellulose, cellulose derivatives (e.g. methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethylcellulose, cellulose acetate phthalate, cellulose acetate succinate, hydroxypropylmethylcellulose phthalate), casein, dextrans, polysaccharides, fibrinogen, poly(D, L lactide), poly (D, L-lactide-co-glycolide), poly(glycolide), poly(hydroxybutyrate), poly(alkylcarbonate), poly(orthoesters), polyesters, poly(hydroxyvaleric acid), polydioxanone, poly(ethylene terephthalate), poly(malic acid), poly(tartronic acid), polyanhydrides, polyphosphazenes, poly(amino acids), and copolymers thereof.

15. The method of claim 1, wherein said plurality of microparticles comprise a material selected from the group consisting of poly methacrylate, polymethyl methacrylate, hydroxapatite, powdered bone, and glass.

16. The method of claim 1, wherein said plurality of microparticles are substantially spherical with a diameter less than 200 μ

m.

17. The method of claim 16, wherein said plurality of microparticles are substantially spherical with a diameter less than 100 μ

m.

18. The method of claim 1, wherein said implantable device further comprises a bioactive agent.

19. The method of claim 18, wherein said bioactive agent comprises an agent selected from the group consisting of a local anesthetic, non-steroidal anti-inflammatory drug, antibiotic, and antineoplastic agent.

20. The method of claim 18, wherein said bioactive agent comprises lidocaine.

21. The method of claim 1, wherein said implantable device further comprises a substrate.

22. The method of claim 21, wherein said substrate comprises a material selected from nylon, Dacron, and Teflon.

23. The method of claim 21, wherein said substrate is coated with said plurality of microparticles and said biodegradable matrix.

24. A canine coxofemoral joint comprising an implantable device, wherein said implantable device comprises collagen and microparticles.

25. The canine coxofemoral joint of claim 24, wherein said collagen comprises bovine collagen.

26. The canine coxofemoral of claim 24, wherein said microparticles are substantially spherical with a diameter less than 200 μ

m.

27. The canine coxofemoral of claim 26, wherein said microparticles are substantially spherical with a diameter less than 100 μ

m.

28. The canine coxofemoral of claim 24, wherein said implantable device further comprises a bioactive agent.

29. The canine coxofemoral of claim 28, wherein said bioactive agent comprises an agent selected from the group consisting of a local anesthetic, non-steroidal anti-inflammatory drug, antibiotic, and antineoplastic agent.

30. The canine coxofemoral of claim 28, wherein said bioactive agent comprises lidocaine.